chronic myeloid leukemia

Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
News
TKI Discontinuation Associated With Improved PROs in CML
12/03/2020
12/03/2020
Journal of Clinical Pathways
Research in Review
Dose Escalation of CML Treatment Improves Molecular Response Rates
08/02/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
Patients with chronic myeloid leukemia (CML) in the chronic phase may achieve molecular response with safe and effective treatment dose escalation, according to a recent study. ----- Related Content CML Mutations...
...
08/02/2017
Journal of Clinical Pathways
Research in Review
CML Treatment Decisions Should Factor in Cardiovascular Disease Risk
07/27/2017
JCP Editors
Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...
Cardiovascular disease rates and its associated risks are increased in patients with chronic myelogenous leukemia (CML) treated by community-based oncologists and should impact treatment decisions, according to a...
...
07/27/2017
Journal of Clinical Pathways
Research in Review
Second TKI Discontinuation Attempt Safe in Patients With CML
07/27/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
Patients with chronic myeloid leukemia (CML) who attempt to discontinue tyrosine kinase inhibitor (TKI) therapy for a second time after a first unsuccessful attempt have strong treatment-free remission rates,...
...
07/27/2017
Journal of Clinical Pathways
Research in Review
Decreasing TKI Dosage Provides Better Outcomes in CML, Lowers Costs
06/29/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who receive half the standard dose of tyrosine kinase inhibitor (TKI) therapy are likely to eliminate most adverse events, drastically reduce costs, and improve...
Patients with chronic myeloid leukemia (CML) who receive half the standard dose of tyrosine kinase inhibitor (TKI) therapy are likely to eliminate most adverse events, drastically reduce costs, and improve...
...
06/29/2017
Journal of Clinical Pathways
Research in Review
TKI Safe and Effective in Pediatric CML
06/15/2017
JCP Editors
A recent study demonstrated high response rates and tolerable safety profiles in pediatric patients with chronic myeloid leukemia (CML) after treatment with a tyrosine kinase inhibitor (TKI). ----- Related...
A recent study demonstrated high response rates and tolerable safety profiles in pediatric patients with chronic myeloid leukemia (CML) after treatment with a tyrosine kinase inhibitor (TKI). ----- Related...
A...
06/15/2017
Journal of Clinical Pathways
Research in Review
TKI Discontinuation Improves Remission Rates for Patients With CML
03/03/2017
JCP Editors
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
Patients with chronic myeloid leukemia (CML) who discontinued treatment with second-generation tyrosine kinase inhibitors (TKIs) benefited from significant treatment-free remission rates, according to research...
...
03/03/2017
Journal of Clinical Pathways
Research in Review
Combining Targeted Therapies Provides Optimal Treatment for CML
11/17/2016
JCP Editors
Using mathematical modeling, researchers have determined the best combination and sequencing of targeted therapies for the treatment of chronic myeloid leukemia (CML). Their results have been published in PLOS...
Using mathematical modeling, researchers have determined the best combination and sequencing of targeted therapies for the treatment of chronic myeloid leukemia (CML). Their results have been published in PLOS...
Using...
11/17/2016
Journal of Clinical Pathways
From the Field
Mock Clinical Pathways: A Method for Exploring the Oncology Clinical Pathway Development Process
05/06/2016
Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...
Abstract: Clinical pathways are a critical structural element in the effort to reduce variation in health care as well as to make costs and outcomes more predictable, measurable, and accountable. A mock clinical...
...
05/06/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use